Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2026-05-19 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
关于对外投资进展暨澄清公告
Legal Proceedings Report Classification · 82% confidence The document is a corporate clarification announcement (“公告”) concerning the company’s external investment progress and related legal risk with Novartis’s Slovenian affiliate. It is not a financial report or earnings release but an update on potential legal claims, negotiations, and risk mitigation steps. This fits the “Legal Proceedings Report” category (LTR).
2026-05-19 Chinese
第六届董事会第九次临时会议决议公告
Regulatory Filings Classification · 75% confidence The document is an announcement of the board of directors’ meeting resolutions approving intra‐group financial assistance. It does not report an AGM voting result, management/head changes, or present full financial statements, nor is it a dividend or share issuance notice. It is a general regulatory announcement that does not fit the more specific categories. Therefore it is classified as a Regulatory Filing (RNS).
2026-05-14 Chinese
关于全资子公司向控股子公司提供财务资助的公告
Capital/Financing Update Classification · 75% confidence The document is a formal stock exchange announcement detailing the board-approved financial assistance (loan) of RMB 50 million from a wholly-owned subsidiary to its controlling subsidiary, including terms, purpose, risk analysis and board resolutions. This is not an earnings or audit report, nor a proxy, dividend or governance guideline. It constitutes a financing activity (intra-group loan) requiring regulatory disclosure. According to the definitions, this falls under Capital/Financing Update (CAP).
2026-05-14 Chinese
关于对外投资进展及重大风险提示的公告
Regulatory Filings Classification · 82% confidence The document is an official corporate announcement detailing progress on an overseas investment project in Slovenia, associated risks, subsidiary financial data, and intended legal actions. It is not a financial report (e.g., annual, interim), earnings release, proxy, or any governance/material change category (no board change, dividend, share issue, etc.). Nor is it a dedicated fundraising or M&A notice. Therefore, it falls into the catch-all “Regulatory Filings” category (RNS).
2026-05-13 Chinese
2025年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and the responsibility of the board and auditors regarding internal control over financial reporting as of December 31, 2025. The document contains an auditor's opinion on the effectiveness of internal control over financial reporting. It is a standalone audit report focused on internal control, not a full annual report or interim report. The document length is short (680 characters), but it contains substantive audit opinion content, not just an announcement. Therefore, it fits the category of Audit Report / Information (AR). FY 2025
2026-04-03 Chinese
2025年环境、社会及治理报告
Environmental & Social Information Classification · 95% confidence The document is titled '2025 博腾股份 环境、社会及治理报告' which translates to '2025 Porton Pharma Environmental, Social and Governance Report'. It covers extensive ESG topics such as environmental compliance, social responsibility, governance structure, ESG management framework, sustainability goals, and performance metrics for the year 2025. The document includes detailed sections on ESG strategy, management, stakeholder engagement, materiality assessment, and governance policies. It references compliance with Shenzhen Stock Exchange ESG reporting guidelines and GRI standards, indicating it is a formal ESG report. The length is substantial (15,000 characters), and it contains substantive content rather than just an announcement or summary. This matches the definition of an Environmental & Social Information (SR) report, which details the company's performance on ESG factors. It is not an Annual Report (10-K), Audit Report (AR), or any other financial or governance report. Therefore, the correct classification is SR with high confidence.
2026-04-03 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.